Connect Sign In
Voriconazole, Quantitation by LC-MS/MS
Ordering Recommendation
Optimize drug therapy and monitor patient adherence.
New York DOH Approval Status
Specimen Required
Specimens collected just before or within 15 minutes of the next dose represent the TROUGH levels. Specimens obtained within 15-30 minutes after the end of I.V. infusion or 45-60 minutes after an IM injection or 90 minutes after oral intake represent the PEAK level. Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Plain Red, Lavender (EDTA), or Green (Sodium or Lithium Heparin).
Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.6 mL)
Frozen.
Whole blood. Gel separator tubes, Light Blue (citrate), or Yellow (SPS or ACD solution).
After separation from cells: Ambient: 48 hours; Refrigerated: 48 hours; Frozen: 6 months
Methodology
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
Performed
Tue-Sat
Reported
1-6 days
Reference Interval
Effective February 19, 2013
| Therapeutic Range (trough) | 1.0-6.0 µg/mL |
| Toxic Level | Greater than 6.0 µg/mL |
Interpretive Data
Voriconazole is an azole antifungal drug indicated to treat invasive aspergillosis, candidiasis, scedosporiosis, and fusariosis infections. The therapeutic range is based on serum, predose (trough) draw collection at steady-state concentration. The pharmacokinetics of voriconazole are influenced by drug-drug interactions when coadministered with drugs metabolized by cytochrome P450 2C9, 2C19 and 3A4 enzymes. Adverse effects may include nausea, vomiting, tachycardia, and elevated serum liver enzymes.
Laboratory Developed Test (LDT)
Note
Hotline History
CPT Codes
80285
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2001738 | Voriconazole, Quantitation by LC-MS/MS | 38370-3 |
Aliases
- Vfend
- Vfend blood concentration
- voriconazole blood concentration
